Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.65 |
| ▸ | DRD4 | P21917 | 5/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 8/20 | 0.53 |
| ▸ | HRH1 | P35367 | 6/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.53 |
| ▸ | HRH2 | P25021 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123140 | 1.00 | HRH4 (0.65) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL123139 | 1.00 | HRH4 (0.65) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL123038 | 1.00 | HRH4 (0.65) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL121788 | 1.00 | HRH4 (0.65) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL121855 | 0.94 | HRH1 (0.62) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL10125507 | 0.93 | HRH4 (0.62) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL10125483 | 0.93 | HRH4 (0.62) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL300367 | 0.90 | HRH4 (0.60) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL300554 | 0.90 | HRH4 (0.60) | HRH4DRD4DRD2HTR2AHRH1 | |
| SCHEMBL300366 | 0.90 | HRH4 (0.60) | HRH4DRD4DRD2HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137180-B1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | claimed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| EP-2137180-A1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | Aryx Therapeutics, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | claimed |
| WO-2008112900-A1 | DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2137180-B1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008112900-A1 | DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | HRH4 1547/4885DRD4 2/4885DRD2 7/4885 |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | HRH4 1547/4885DRD4 2/4885DRD2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.